AstraZeneca PLC (NASDAQ:AZN) Holdings Boosted by Coldstream Capital Management Inc.

Coldstream Capital Management Inc. raised its position in shares of AstraZeneca PLC (NASDAQ:AZN) by 4.1% during the 3rd quarter, Holdings Channel.com reports. The firm owned 26,777 shares of the company’s stock after acquiring an additional 1,050 shares during the period. Coldstream Capital Management Inc.’s holdings in AstraZeneca were worth $2,086,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of AZN. Martin Investment Management LLC grew its position in AstraZeneca by 2.8% during the third quarter. Martin Investment Management LLC now owns 284,204 shares of the company’s stock valued at $22,571,000 after purchasing an additional 7,615 shares in the last quarter. Integrated Advisors Network LLC grew its holdings in shares of AstraZeneca by 46.6% during the 3rd quarter. Integrated Advisors Network LLC now owns 43,610 shares of the company’s stock valued at $3,398,000 after acquiring an additional 13,860 shares in the last quarter. Creative Planning increased its stake in shares of AstraZeneca by 8.0% in the third quarter. Creative Planning now owns 224,751 shares of the company’s stock worth $17,510,000 after acquiring an additional 16,692 shares during the last quarter. Northcape Wealth Management LLC purchased a new stake in shares of AstraZeneca during the second quarter worth $269,000. Finally, Soros Fund Management LLC boosted its position in AstraZeneca by 8.2% during the third quarter. Soros Fund Management LLC now owns 2,652,771 shares of the company’s stock valued at $206,677,000 after purchasing an additional 201,233 shares during the last quarter. Hedge funds and other institutional investors own 20.35% of the company’s stock.

AstraZeneca Stock Up 0.3 %

Shares of AstraZeneca stock opened at $67.40 on Thursday. AstraZeneca PLC has a 12-month low of $60.47 and a 12-month high of $87.68. The company has a quick ratio of 0.71, a current ratio of 0.93 and a debt-to-equity ratio of 0.71. The stock has a 50 day moving average price of $70.61 and a two-hundred day moving average price of $76.86. The stock has a market capitalization of $208.98 billion, a P/E ratio of 32.25, a PEG ratio of 1.20 and a beta of 0.45.

AstraZeneca (NASDAQ:AZN) last posted its quarterly earnings data on Tuesday, November 12th. The company reported $1.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.01 by $0.03. AstraZeneca had a net margin of 12.68% and a return on equity of 30.01%. The business had revenue of $13.57 billion during the quarter, compared to the consensus estimate of $13.08 billion. During the same period in the prior year, the firm earned $0.87 EPS. AstraZeneca’s quarterly revenue was up 18.0% compared to the same quarter last year. Equities analysts expect that AstraZeneca PLC will post 4.11 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on AZN. Erste Group Bank raised AstraZeneca from a “hold” rating to a “buy” rating in a research note on Wednesday, September 11th. UBS Group raised shares of AstraZeneca from a “sell” rating to a “neutral” rating in a research report on Wednesday, November 20th. Finally, Deutsche Bank Aktiengesellschaft raised shares of AstraZeneca from a “sell” rating to a “hold” rating in a research report on Wednesday, November 6th. Three analysts have rated the stock with a hold rating, seven have given a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, AstraZeneca currently has an average rating of “Moderate Buy” and a consensus target price of $89.75.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.